Shattuck Labs, Inc. (STTK) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Shattuck Labs, Inc.'s filing signal turned positive.

Shattuck Labs is a clinical-stage biotechnology company focused on developing first-in-class monoclonal and bispecific antibodies targeting the Death Receptor 3 (DR3) pathway for inflammatory and immune-mediated diseases. Its lead candidate, SL-325, is a DR3 blocking antibody designed to offer a more complete and durable blockade of the DR3/TL1A pathway compared to TL1A blocking antibodies, potentially leading to improved clinical remission rates in conditions like Inflammatory Bowel Disease (IBD). The company's strategy leverages its protein engineering expertise to advance SL-325 through clinical trials, with a Phase 1 trial in healthy volunteers expected to complete in Q2 2026 and a Phase 2 trial in Crohn's Disease patients planned for Q3 2026. Shattuck is also developing other DR3-based bispecific antibodies and aims to differentiate itself through a potentially superior immunogenicity profile and mechanism of action.

Revenue is primarily driven by license and collaboration agreements. In 2025, license revenue was generated from an agreement with Kayak Therapeutics, Inc. In 2024, collaboration revenue was recognized from agreements with Ono Pharmaceutical Co., Ltd. and ImmunoGen, Inc.